Welcome to our dedicated page for Conmed news (Ticker: CNMD), a resource for investors and traders seeking the latest updates and insights on Conmed stock.
CONMED Corporation reports news on its medical technology business, which provides surgical devices and equipment used by surgeons and other healthcare professionals across multiple specialties. Company updates commonly cover sales trends, domestic and international revenue, GAAP and adjusted earnings, full-year outlooks, and management presentations in the healthcare sector.
Recurring announcements also address portfolio optimization, including the exit or reduction of certain gastroenterology products, and the company’s focus on minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair. Other corporate news includes finance leadership changes and operating initiatives tied to supply chain execution, product rationalization, and margin profile.
CONMED (NYSE: CNMD) announced that its FDA-cleared AirSeal® Robotic Solution now has an expanded indication for use with Intuitive’s 8 mm hex cannulas on the da Vinci 5 platform. This builds on its existing indication for Intuitive 8 mm round cannulas.
With this change, AirSeal Robotic Solution is indicated for use across Intuitive’s da Vinci X, da Vinci Xi, and da Vinci 5 systems. According to CONMED, the expanded indication supports compatibility with Intuitive’s latest platform architecture and is backed by over 40 clinical studies on low-pressure insufflation, targeting enhanced patient outcomes, procedural efficiency, and clearer product communication for hospitals and surgeons.
CONMED (NYSE: CNMD) will participate in the Society of Robotic Surgery 2026 Annual Meeting, held July 23-26, 2026 in Fort Lauderdale, FL. Professor Nikhil Vasdev will present data from a 40-patient randomized controlled clinical trial comparing CONMED’s AirSeal Insufflation System with Stryker’s PneumoClear during robotic prostatectomy.
The trial used intra-operative artificial intelligence to measure nociceptive (pain) events at low-pressure pneumoperitoneum (8 mmHg). AirSeal showed fewer significant nociceptive events per hour (20.7 vs. 33.5, p = 0.041), along with shorter procedure and console times (both p = 0.045) and reduced blood loss (p < 0.001). Results were published in JUI Compass in May 2026. CONMED will also host a session on low-pressure insufflation’s impact on intraoperative performance and patient recovery on Friday, July 24 at 12:30 PM ET.
CONMED (NYSE: CNMD) will report its second quarter 2026 financial results after the market close on Wednesday, July 29, 2026. Management will host a conference call at 4:30 p.m. ET to discuss the results, accessible by pre-registering for telephone details or via webcast in the Investors section of CONMED's website. A webcast replay will be available about one hour after the call ends.
CONMED (NYSE: CNMD) appointed John E. Gallagher as Chief Financial Officer, effective July 15, 2026, succeeding Todd Garner.
Gallagher brings nearly three decades of finance experience, including CFO roles at Certara and Cue Health and senior leadership positions at BD. Garner will remain in an advisory role through November 2, 2026.
CONMED (NYSE: CNMD) appointed Celine Martin and Jeff Mirviss to its Board of Directors, effective July 1, 2026. The Board will expand to nine members.
Martin joins the Audit and Strategy Committees; Mirviss joins the Compensation and Corporate Governance and Nominating Committees, bringing decades of MedTech leadership from Johnson & Johnson and Boston Scientific.
CONMED (NYSE: CNMD) reported Q1 2026 results for the quarter ended March 31, 2026: net sales $317.0M (down 1.3% YoY, -2.9% constant currency), GAAP diluted EPS $0.45 and adjusted diluted EPS $0.89. Gross profit was $183.4M (57.9% of sales).
Management raised 2026 organic constant-currency revenue growth to ~5.0%–6.5% and now expects full-year reported revenue of $1.350B–$1.375B; adjusted diluted EPS guidance remains $4.30–$4.45.
CONMED (NYSE: CNMD) will report first quarter 2026 financial results after market close on April 29, 2026. Management will host a conference call at 4:30 p.m. ET the same day.
Investors can pre-register for telephone access, join a live webcast via the company's Investors page at www.conmed.com, and view a replay approximately one hour after the call ends.
CONMED (NYSE: CNMD) reported Q4 2025 sales of $373.2M (+7.9% YoY) and full-year 2025 sales of $1,374.7M (+5.2% YoY). GAAP diluted EPS was $0.54 in Q4 and $1.51 for FY 2025; adjusted diluted EPS were $1.43 (Q4) and $4.59 (FY).
The company issued 2026 guidance of revenue between $1.345B–$1.375B and adjusted diluted EPS of $4.30–$4.45, noting a modest currency tailwind and organic growth excluding gastroenterology sales.
CONMED (NYSE: CNMD) announced that Todd Garner will step down as Chief Financial Officer effective March 15, 2026 and will remain in an advisory role through November 2, 2026. The company has started a comprehensive search, supported by a leading executive search firm, to identify a new CFO. Management thanked Garner for eight years of service and said his departure is not related to any disagreement over financial statements or disclosures. CONMED also reaffirmed its full-year 2025 consolidated revenue and adjusted EPS guidance previously issued on November 5, 2025.
CONMED (NYSE: CNMD) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 3:00 p.m. PT / 6:00 p.m. ET in San Francisco.
Presenters will be Patrick J. Beyer, president and CEO, and Todd W. Garner, EVP and CFO. A live audio webcast will be available via the company’s Investors page at www.conmed.com, with a replay accessible after the event.